Phase II Trial of BCNU Plus O6-Benzylguanine in the Treatment of Patients With Recurrent or Progressive Cerebral Anaplastic Gliomas
OBJECTIVES: I. Determine the activity of carmustine and O6-benzylguanine in patients with
recurrent or progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma
resistant to nitrosourea. II. Determine the toxic effects of this regimen in these patients.
OUTLINE: Patients receive O6-benzylguanine IV over 1 hour, followed 1 hour later by
carmustine IV over 1 hour on day 1. Treatment repeats every 6 weeks in the absence of
disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 18-32 patients will be accrued for this study within 12-18
Primary Purpose: Treatment
Henry S. Friedman, MD
Duke Cancer Institute
United States: Federal Government
|Duke Comprehensive Cancer Center||Durham, North Carolina 27710|